Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy

Nature Reviews Clinical Oncology, Published online: 26 June 2023; doi:10.1038/s41571-023-00785-8Many studies attempting to identify biomarkers for predicting of immune-checkpoint inhibitor (ICI) efficacy have led to the description of Gut OncoMicrobiome Signatures (GOMS). Several GOMS support an association between oncogenesis and intestinal dysbiosis, and other GOMS are shared between patients with several cancer subtypes and individuals with seemingly unrelated chronic inflammatory disorders. The authors of this Review discuss these patterns as well as the findings from a meta-analysis of GOMS associated with clinical benefit from ICIs, and propose practical guidelines to incorporate GOMS in decision-making in immuno-oncology.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research